A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis

RATIONALE: Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first authors to report a case of Hodgkin lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Charakopoulos, Emmanouil, Spyrou, Ioannis, Viniou, Nora-Athina, Giannakopoulou, Nefeli, Hatzidavid, Sevastianos, Diamantopoulos, Panagiotis Theodorou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249998/
https://www.ncbi.nlm.nih.gov/pubmed/32481271
http://dx.doi.org/10.1097/MD.0000000000020048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249998/
https://www.ncbi.nlm.nih.gov/pubmed/32481271
http://dx.doi.org/10.1097/MD.0000000000020048

Ejemplares similares